PCDHGC3 silencing promotes clear cell renal cell carcinoma metastasis via mTOR/HIF2α activation, lipid metabolism rewiring, and ferroptosis evasion

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009.

Google Scholar 

Qi X, Li Q, Che X, Wang Q, Wu G. The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC. Front Oncol. 2021;11:727778.

Google Scholar 

Angulo JC, Shapiro O. The changing therapeutic landscape of metastatic renal cancer. Cancers. 2019;11:1227.

Google Scholar 

Kaelin WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007;13:680s–684s.

Google Scholar 

Hager M, Haufe H, Lusuardi L, Schmeller N, Kolbitsch C. PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases. Cancer Invest. 2011;29:427–38.

Google Scholar 

Meng L, Collier KA, Wang P, Li Z, Monk P, Mortazavi A, et al. EmergIng immunotherapy approaches for advanced clear cell renal cell carcinoma. Cells. 2023;13:34.

Google Scholar 

Wilson NR, Acikgoz Y, Hasanov E. Advances in non-clear cell renal cell carcinoma management: from heterogeneous biology to treatment options. Int J Cancer. 2024;154:947–61.

Google Scholar 

Nguyen CB, Oh E, Bahar P, Vaishampayan UN, Else T, Alva AS. Novel approaches with HIF-2α targeted therapies in metastatic renal cell carcinoma. Cancers. 2024;16:601.

Google Scholar 

Wu X, Lazris D, Wong R, Tykodi SS. Belzutifan for the treatment of renal cell carcinoma. Ther Adv Med Oncol. 2025;17:17588359251317846.

Google Scholar 

van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14:121–34.

Google Scholar 

Na T-Y, Schecterson L, Mendonsa AM, Gumbiner BM. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci USA. 2020;117:5931–7.

Google Scholar 

Peek SL, Mah KM, Weiner JA. Regulation of neural circuit formation by protocadherins. Cell Mol Life Sci. 2017;74:4133–57.

Google Scholar 

Flaherty E, Maniatis T. The role of clustered protocadherins in neurodevelopment and neuropsychiatric diseases. Curr Opin Genet Dev. 2020;65:144–50.

Google Scholar 

Mountoufaris G, Canzio D, Nwakeze CL, Chen WV, Maniatis T. Writing, reading, and translating the clustered protocadherin cell surface recognition code for neural circuit assembly. Annu Rev Cell Dev Biol. 2018;34:471–93.

Google Scholar 

Keeler AB, Molumby MJ, Weiner JA. Protocadherins branch out: multiple roles in dendrite development. Cell Adh Migr. 2015;9:214–26.

Google Scholar 

Dallosso AR, Øster B, Greenhough A, Thorsen K, Curry TJ, Owen C, et al. Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene. 2012;31:4409–19.

Google Scholar 

Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai H-H, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms’ tumor. PLoS Genet. 2009;5:e1000745.

Google Scholar 

Bernardo-Castiñeira C, Valdés N, Celada L, Martinez ASJ, Sáenz-de-Santa-María I, Bayón GF, et al. Epigenetic deregulation of protocadherin PCDHGC3 in pheochromocytomas/paragangliomas associated with SDHB mutations. J Clin Endocrinol Metab. 2019;104:5673–92.

Google Scholar 

Cubiella T, Celada L, San-Juan-Guardado J, Rodríguez-Aguilar R, Suárez-Priede Á, Poch M, et al. PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas. J Pathol. 2024;263:418–28.

Google Scholar 

Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenet. 2019;11:100.

Google Scholar 

Lobas MA, Helsper L, Vernon CG, Schreiner D, Zhang Y, Holtzman MJ, et al. Molecular heterogeneity in the choroid plexus epithelium: the 22-member γ-protocadherin family is differentially expressed, apically localized, and implicated in CSF regulation. J Neurochem. 2012;120:913–27.

Google Scholar 

Herrada-Manchón H, Celada L, Rodríguez-González D, Alejandro Fernández M, Aguilar E, Chiara M-D. Three-dimensional bioprinted cancer models: a powerful platform for investigating tunneling nanotube-like cell structures in complex microenvironments. Mater Sci Eng C Mater Biol Appl. 2021;128:112357.

Google Scholar 

Győrffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation. 2024;5:100625.

Google Scholar 

Díez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetcs Chromatin. 2015;8:22.

Google Scholar 

Badoiu SC, Greabu M, Miricescu D, Stanescu-Spinu I-I, Ilinca R, Balan DG, et al. PI3K/AKT/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: crosstalk with the VHL/HIF axis. Int J Mol Sci. 2023;24:8391.

Google Scholar 

Xu Q, Krause M, Samoylenko A, Vainio S. Wnt signaling in renal cell carcinoma. Cancers. 2016;8:57.

Google Scholar 

Roviello G, De Gennaro I, Vascotto I, Venturi G, D’Angelo A, Winchler C, et al. Hypoxia-inducible factor in renal cell carcinoma: from molecular insights to targeted therapies. Genes. 2024;16:6.

Google Scholar 

Kucejova B, Peña-Llopis S, Yamasaki T, Sivanand S, Tran TAT, Alexander S, et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res. 2011;9:1255–65.

Google Scholar 

Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995;1:822–6.

Google Scholar 

Qiu B, Ackerman D, Sanchez DJ, Li B, Ochocki JD, Grazioli A, et al. HIF2α-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 2015;5:652–67.

Google Scholar 

Chen WV, Nwakeze CL, Denny CA, O’Keeffe S, Rieger MA, Mountoufaris G, et al. Pcdhαc2 is required for axonal tiling and assembly of serotonergic circuitries in mice. Science. 2017;356:406–11.

Google Scholar 

Steffen DM, Hanes CM, Mah KM, Valiño Ramos P, Bosch PJ, Hinz DC, et al. A Unique role for protocadherin γC3 in promoting dendrite arborization through an axin1-dependent mechanism. J Neurosci. 2023;43:918–35.

Google Scholar 

Meltzer S, Boulanger KC, Chirila AM, Osei-Asante E, DeLisle M, Zhang Q, et al. γ-Protocadherins control synapse formation and peripheral branching of touch sensory neurons. Neuron. 2023;111:1776–94.e10.

Google Scholar 

Garrett AM, Bosch PJ, Steffen DM, Fuller LC, Marcucci CG, Koch AA, et al. CRISPR/Cas9 interrogation of the mouse Pcdhg gene cluster reveals a crucial isoform-specific role for Pcdhgc4. PLoS Genet. 2019;15:e1008554.

Google Scholar 

Leon WRM, Steffen DM, Dale-Huang FR, Rakela B, Breevoort A, Romero-Rodriguez R, et al. The clustered gamma protocadherin PcdhγC4 isoform regulates cortical interneuron programmed cell death in the mouse cortex. Proc Natl Acad Sci USA. 2024;121:e2313596120.

Google Scholar 

Chen J, Lu Y, Meng S, Han MH, Lin C, Wang X. α- and γ-protocadherins negatively regulate PYK2. J Biol Chem. 2009;284:2880–90.

Google Scholar 

Keeler AB, Schreiner D, Weiner JA. Protein kinase C phosphorylation of a γ-protocadherin C-terminal lipid binding domain regulates focal adhesion kinase inhibition and dendrite arborization. J Biol Chem. 2015;290:20674–86.

Google Scholar 

Mah KM, Houston DW, Weiner JA. The γ-Protocadherin-C3 isoform inhibits canonical Wnt signalling by binding to and stabilizing Axin1 at the membrane. Sci Rep. 2016;6:31665.

Google Scholar 

Ahmed R, Ornstein MC. Targeting HIF-2 alpha in renal cell carcinoma. Curr Treat Options Oncol. 2023;24:1183–98.

Google Scholar 

González-Larriba JL, Maroto P, Durán I, Lambea J, Flores L, Castellano D, et al. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges. Expert Rev Anticancer Ther. 2017;17:217–26.

Google Scholar 

Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem. 2008;283:34495–9.

Google Scholar 

Garrett AM, Schreiner D, Lobas MA, Weiner JA. γ-protocadherins control cortical dendrite arborization by regulating the activity of a FAK/PKC/MARCKS signaling pathway. Neuron. 2012;74:269–76.

Google Scholar 

Qiu L, Sun Y, Ning H, Chen G, Zhao W, Gao Y. The scaffold protein AXIN1: gene ontology, signal network, and physiological function. Cell Commun Signal. 2024;22:77.

Google Scholar 

Tan SK, Hougen HY, Merchan JR, Gonzalgo ML, Welford SM. Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets. Nat Rev Urol. 2023;20:48–60.

Google Scholar 

Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34:1675–99.

Google Scholar 

Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37:2285–301.

Google Scholar 

Pan J, Fan Z, Wang Z, Dai Q, Xiang Z, Yuan F, et al. CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3β/β-catenin pathway. J Exp Clin Cancer Res. 2019;38:52.

Google Scholar 

Jiang M, Wu N, Xu B, Chu Y, Li X, Su S, et al. Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Theranostics. 2019;9:5359–73.

Google Scholar 

Corbet C, Bastien E, Santiago de Jesus JP, Dierge E, Martherus R, Vander Linden C, et al. TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 2020;11:454.

Google Scholar 

Wen J, Min X, Shen M, Hua Q, Han Y, Zhao L, et al. ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exp Clin Cancer Res. 2019;38:401.

Google Scholar 

Guo W, Abudumijiti H, Xu L, Hasim A. CD147 promotes cervical cancer migration and invasion by up-regulating fatty acid synthase expression. Int J Clin Exp Pathol. 2019;12:4280–8.

Google Scholar 

Jonasch E, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024;196:113434.

Google Scholar 

Choueiri TK, Powles T, Voss MH, Plimack ER, Gurney H, Song Y, et al. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. Future Oncol. 2023;19:2631–40.

Google Scholar 

Chan KH, Li N, Lador R, Amsbaugh M, Gonzalez A, Cen P. Belzutifan, HIF-2α inhibitor, and clear cell renal cell carcinoma with somatic Von-Hippel-Lindau loss-of-function mutation. J Investig Med High Impact Case Rep. 2024;12:23247096241231641.

Google Scholar